A recent study published in the journal JAMA evaluated the efficacy and side effects of donanemab. They aimed to use this antibody to clear brain amyloid plaque in randomized participants with early symptomatic Alzheimer disease (AD) with low/medium or high tau pathology.

Read more “Donanemab: A trailblazer for Alzheimer’s disease treatment?”